Yu Liu1, Yuanjun Wang2, Weiqing Tang1, Mengda Jiang1, Kaicheng Li3,4, Xiaofeng Tao5. 1. Department of Radiology, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, No. 639, ZhiZaoJu Road, Shanghai, 200011, China. 2. Institute of Medical Imaging and Engineering, University of Shanghai for Science and Technology, Shanghai, China. 3. Department of Radiology, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, No. 639, ZhiZaoJu Road, Shanghai, 200011, China. kaichengli2012@126.com. 4. Hainan West Central Hospital, Danzhou, Hainan, China. kaichengli2012@126.com. 5. Department of Radiology, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, No. 639, ZhiZaoJu Road, Shanghai, 200011, China. xiaofengtao2012@126.com.
Abstract
OBJECTIVE: To investigate the therapeutic efficacy of Iodine-125 (125I) seeds brachytherapy to pancreatic ductal adenocarcinoma (PDAC) xenografts via multiparametric magnetic resonance imaging (MRI) analysis. MATERIALS AND METHODS: Twenty mice were implanted subcutaneously with SW-1990 PDAC xenografts. The tumor-bearing mice were randomly divided into 125I seeds group (n = 10) and blank control group (n = 10). Treatment response was monitored by diffusion-weighted magnetic resonance imaging (DW-MRI) and dynamic contrast-enhanced MRI (DCE-MRI) obtained 1 day before, 14 and 60 days after treatment. Imaging results were correlated with histopathology. RESULTS: 125I seeds brachytherapy resulted in a significant increase in mean tumor apparent diffusion coefficient (ADC) values compared to the control at 14 and 60 days after treatment (p < 0.05). DCE-MRI showed a significant decrease in the perfusion parameters including Ktrans and Kep (p < 0.05). The mean ADCs within the peripheral region of the tumors were linearly proportional to the mean apoptotic cell density (p = 0.015; Spearman's coefficient = 0.945). The Ktrans and Kep were linearly proportional to microvessel density (MVD) (p = 0.043, 0.047; Spearman's coefficient = 0.891, 0.884). CONCLUSION: 125I seeds brachytherapy leads to effective inhibition of PDAC cell proliferation, higher degree of necrosis and necroptosis, and lower MVD. Both DW-MRI and DCE-MRI are feasible to monitor a response to 125I seeds brachytherapy in the PDAC xenografts. This paper shows an original project concerning about a possible palliative treatment not only in a murine model (preclinical setting) but also in humans.
OBJECTIVE: To investigate the therapeutic efficacy of Iodine-125 (125I) seeds brachytherapy to pancreatic ductal adenocarcinoma (PDAC) xenografts via multiparametric magnetic resonance imaging (MRI) analysis. MATERIALS AND METHODS: Twenty mice were implanted subcutaneously with SW-1990 PDAC xenografts. The tumor-bearing mice were randomly divided into 125I seeds group (n = 10) and blank control group (n = 10). Treatment response was monitored by diffusion-weighted magnetic resonance imaging (DW-MRI) and dynamic contrast-enhanced MRI (DCE-MRI) obtained 1 day before, 14 and 60 days after treatment. Imaging results were correlated with histopathology. RESULTS: 125I seeds brachytherapy resulted in a significant increase in mean tumor apparent diffusion coefficient (ADC) values compared to the control at 14 and 60 days after treatment (p < 0.05). DCE-MRI showed a significant decrease in the perfusion parameters including Ktrans and Kep (p < 0.05). The mean ADCs within the peripheral region of the tumors were linearly proportional to the mean apoptotic cell density (p = 0.015; Spearman's coefficient = 0.945). The Ktrans and Kep were linearly proportional to microvessel density (MVD) (p = 0.043, 0.047; Spearman's coefficient = 0.891, 0.884). CONCLUSION: 125I seeds brachytherapy leads to effective inhibition of PDAC cell proliferation, higher degree of necrosis and necroptosis, and lower MVD. Both DW-MRI and DCE-MRI are feasible to monitor a response to 125I seeds brachytherapy in the PDAC xenografts. This paper shows an original project concerning about a possible palliative treatment not only in a murine model (preclinical setting) but also in humans.
Authors: Pari V Pandharipande; Curtis Heberle; Emily C Dowling; Chung Yin Kong; Angela Tramontano; Katherine E Perzan; William Brugge; Chin Hur Journal: Radiology Date: 2016-01 Impact factor: 11.105
Authors: Hyunki Kim; Karri D Folks; Lingling Guo; Jeffery C Sellers; Naomi S Fineberg; Cecil R Stockard; William E Grizzle; Donald J Buchsbaum; Desiree E Morgan; James F George; Kurt R Zinn Journal: Mol Imaging Date: 2011-06 Impact factor: 4.488
Authors: Dong Soo Park; In Hyuck Gong; Don Kyung Choi; Jin Ho Hwang; Hyun Soo Shin; Jong Jin Oh Journal: World J Urol Date: 2013-04-27 Impact factor: 4.226
Authors: Kenneth E Pengel; Bas B Koolen; Claudette E Loo; Wouter V Vogel; Jelle Wesseling; Esther H Lips; Emiel J Th Rutgers; Renato A Valdés Olmos; Marie Jeanne T F D Vrancken Peeters; Sjoerd Rodenhuis; Kenneth G A Gilhuijs Journal: Eur J Nucl Med Mol Imaging Date: 2014-04-29 Impact factor: 9.236